



Press  
release

Montpellier, November 27, 2017 - 5:45 pm CET

## Intrasense brought to light in the RSNA 2017 "Prostate MRI" workshop

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, will provide Myrian® as a pedagogical tool for the "Prostate MRI" workshop at RSNA 2017, international reference congress of radiology.

Internationally renowned teachers will guide the trainees - 500 radiologists - about the MRI reference method PI-RADS 2, using Myrian® XP-Prostate software.

This workshop, a first for Intrasense, will benefit from high exposure from November 26 to December 1, in the Radiological Society of North America Congress ([RSNA](#)), the largest radiology congress worldwide, bringing together in Chicago radiologists from 136 countries.

### [A workshop dedicated to reference method PI-RADS 2](#)

The several sessions of the "Prostate MRI" workshop will review multi-parametric cases with the MRI Prostate Imaging Reporting and Data System (PI-RADS 2) method, available within Myrian® prostate module.

PI-RADS 2 is a world-reference methodology for MRI, a key contribution to a better efficiency in sharing of information in the chain of care of prostate treatment.

This method optimizes patient management and follow-up by enabling physicians to score the probability of the presence of a prostate cancer in patients, with optimized recognition and differentiation from benign pathology.

### [Prostate cancer, a global health issue](#)

Two men out of nine will develop a clinical form of prostate cancer in their lifetime. Second most frequent cancer for men in the world, prostate cancer affects more than 1.1 million cases and will increase by +75% by 2030 (*source: WHO - 2012*). It represents a real challenge for MRI detection, requiring adapted tools, such as Intrasense's Myrian® XP-Prostate software, with well-trained qualified users.

*"We are really honored that Myrian® has been the selected solution for this reference and large audience scientific workshop. Since its creation, Myrian® XP-Prostate integrates the PI-RADS scoring mechanism, giving easy access to structured reports with localization diagrams, providing valuable information to clinicians."* comments Philippe MICHELON, Product Director at Intrasense.



## About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 45 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and invested more than 10 million euros in Research & Development since its creation.

For more information, please visit [www.intrasense.fr](http://www.intrasense.fr).

## Contacts

Intrasense  
Stéphane Chemouny  
Chairman and Chief Executive Officer  
Christophe Lamboeuf  
Deputy Managing Director  
Tel: +33 4 67 130 130  
[investor@intrasense.fr](mailto:investor@intrasense.fr)

NewCap  
Investor Relations and Financial  
Communication  
Valentine Brouchet  
Pierre Laurent  
Tel: + 33 1 44 71 94 96  
[intrasense@newcap.eu](mailto:intrasense@newcap.eu)

